A phase II, randomized, study of weekly APG101+reirradiation versus reirradiation in progressive glioblastoma

Clinical Cancer Research

Volumn 20, Issue 24, 2014, Pages 6304-6313

  Wick, Wolfgang ^a,b   Fricke, Harald ^c   Junge, Klaus ^d   Kobyakov, Grigory ^e   Martens, Tobias ^f   Heese, Oliver ^f,i   Wiestler, Benedikt ^a,b   Schliesser, Maximilian G ^b   Von Deimling, Andreas ^b,g   Pichler, Josef ^h   Vetlova, Elena ^e   Harting, Inga ^g   Debus, Jüurgen ^g   Hartmann, Christian ^b,g,j   Kunz, Claudia ^c   Platten, Michael ^a,b   Bendszus, Martin ^g   Combs, Stephanie E ^g  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c APOGENIX GMBH   (Germany)

^d Premier Research   (United States)

^e BURDENKO NEUROSURGICAL INSTITUTE   (Russian Federation)

^f UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^g UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^h Landesnervenklinik ^*  (Austria)

ⁱ HELIOS Medical Center Schwerin   (Germany)

^j HANNOVER MEDICAL SCHOOL   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

APG 101; FAS LIGAND; HYBRID PROTEIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; APG101; BIOLOGICAL MARKER; FAS ANTIGEN; IMMUNOGLOBULIN G;

ADULT; AGED; APHASIA; ARTICLE; BRAIN EDEMA; CANCER GROWTH; CANCER RADIOTHERAPY; CD95L GENE; COGNITIVE DEFECT; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; CONVULSION; COORDINATION DISORDER; DEATH; DEPRESSION; DNA METHYLATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FOCAL EPILEPSY; GLIOBLASTOMA; HEADACHE; HEMIPARESIS; HUMAN; HUMAN TISSUE; HYPESTHESIA; LIMB PAIN; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; NAUSEA; NEUROLOGIC DISEASE; OPEN STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; PROMOTER REGION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; TUMOR VOLUME; VOMITING; CLINICAL TRIAL; DRUG ADMINISTRATION; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROGNOSIS; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; ANTIGENS, CD95; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; COMBINED MODALITY THERAPY; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLIOBLASTOMA; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PROGNOSIS; QUALITY OF LIFE; RECOMBINANT FUSION PROTEINS; TREATMENT OUTCOME; TUMOR BURDEN; YOUNG ADULT;

EID: 84919648669     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-0951-T     Document Type: Article

References (35)

1. Weller M, Cloughesy T, Perry JR, Wick W. Standards of care for treatment of recurrent glioblastoma-are we there yet? Neuro Oncol 2013;15:4-27.
2. Ohgaki H. Epidemiology of brain tumours. Methods Mol Biol 2009; 472:323-42.
3. Central Brain Tumour Registry of the United States: 2009- 2010 CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumours Diagnosed in Eighteen States in 2002-2006, 2009.
4. Batchelor TT, Mulholland P, Neyns B, Nabors LB, Campone M, Wick A, et al. Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. J Clin Oncol 2013; 31:3212-8.
5. Taal W, Oosterkamp HM, Walenkamp AM, Dubbink HJ, Beerepoot LV, Hanse MC, et al. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. Lancet Oncol 2014;15:943-53.
6. Wick W, Puduvalli VK, Chamberlain M, van den Bent MJ, Carpentier AF, Cher LM, et al. Enzastaurin (ENZ) versus lomustine (CCNU) in the treatment of recurrent, intracranial glioblastoma: a phase III study. J Clin Oncol 2010;28:1168-74.
7. Perry JR, Belanger K, Mason WP, Fulton D, Kavan P, Easaw J, et al. Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. J Clin Oncol 2010;28:2051-7.
8. Wick A, Felsberg J, Steinbach JP, Herrlinger U, Platten M, Blaschke B, et al. Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. J Clin Oncol 2007;25: 3357-61.
9. Combs SE, Thilmann C, Edler L, Debus J, Schulz-Ertner D. Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: long-term results in 172 patients treated in a single Institution. J Clin Oncol 2005;23:8863-9.
10. Fogh SE, Andrews DW, Glass J, Curran W, Glass C, Champ C, et al. Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent high-grade gliomas. J Clin Oncol 2010;28:3048-53.
11. Chen L, Park SM, Tumanov AV, Hau A, Sawada K, Feig C, et al. CD95 promotes tumour growth. Nature 2010;465:492-6.
12. Kleber S, Sancho-Martinez I, Wiestler B, Beisel A, Gieffers C, Hill O, et al. Yes and PI3K bind CD95 to signal invasion of glioblastoma. Cancer Cell 2008;13:235-48.
13. Roth W, Isenmann S, Nakamura M, Platten M, Wick W, Kleihues P. Soluble decoy receptor 3 is expressed by malignant gliomas and suppresses CD95 ligand-induced apoptosis and chemotaxis. Cancer Res 2001;61:2759-65.
14. Wisniewski P, Ellert-Miklaszewska A, Kwiatkowska A, Kaminska B. Non-apoptotic Fas signaling regulates invasiveness of glioma cells and modulates MMP-2 activity via NFkappaB- TIMP-2 pathway. Cell Signal 2009;22:212-20.
15. Wild-Bode C, Weller M, Rimner A, Dichgans J, Wick W. Sublethal irradiation promotes migration and invasiveness of glioma cells: implications for radiotherapy of human glioblastoma. Cancer Res 2001;61: 2744-50.
16. Park CM, Park MJ, Kwak HJ, Lee HC, Kim MS, Lee SH, et al. Ionizing radiation enhances matrix metalloproteinase-2 secretion and invasion of glioma cells through Src/epidermal growth factor receptor-mediated p38/Akt and phosphatidylinositol 3-kinase/Akt signaling pathways. Cancer Res 2006;66:8511-9.
17. Martinou M, Giannopoulou E, Malatara G, Argyriou AA, Kalofonos HP, Kardamakis D. Ionizing radiation affects epidermal growth factor receptor signalling and metalloproteinase secretion in glioma cells. Cancer Genomics Proteomics 2004;8:33-8.
18. Zhai GG, Malhotra R, Delaney M, Latham D, Nestler U, Zhang M. Radiation enhances the invasive potential of primary glioblastoma cells via activation of the Rho signaling pathway. J Neurooncol 2006;76:227-37.
19. Tuettenberg J, Seiz M, Debatin KM, Hollburg W, von Staden M, Thiemann M, et al. Pharmacokinetics, pharmacodynamics, safety and tolerability of APG101, a CD95-Fc fusion protein, in healthy volunteers and two glioma patients. Int Immunopharmacol 2012;13:93-100.
20. Letellier E, Kumar S, Sancho-Martinez I, Krauth S, Funke-Kaiser A, Laudenklos S, et al. CD95-ligand on peripheral myeloid cells activates Syk kinase to trigger their recruitment to the inflammatory site. Immunity 2010;32:240-52.
21. Motz GT, Santoro SP, Wang LP, Garrabrant T, Lastra RR, Hagemann IS, et al. Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. Nat Med 2014;20:607-15.
22. Groenvold M, Petersen MA, Aaronson NK, Arraras JI, Blazeby JM, Bottomley A, et al. The development of the EORTC QLQ-C15-PAL: a shortened questionnaire for cancer patients in palliative care. Eur J Cancer 2006;42:55-64.
23. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990;8:1277-80.
24. Wen PY, Macdonald DA, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology (RANO) working group. J Clin Oncol 2010;28:1963-72
25. th ed. World Health Organization classification of tumours. Lyon, France: International Agency for Research on Cancer; 2007;309 p.
26. Capper D, Zentgraf H, Balss J, Hartmann C, von Deimling A. Monoclonal antibody specific for IDH1 R132H mutation. Acta Neuropathol 2009;118:599-601.
27. Christians A, Hartmann C, Benner A, Meyer J, von Deimling A, Weller M, et al. Prognostic value of three different methods of MGMT promoter methylation analysis in a prospective trial on newly diagnosed glioblastoma. PLoS ONE 2012;7:e33449.
28. Simon R. Designs for efficient clinical trials. Oncology 1989;3:43-9.
29. Combs SE, Edler L, Rausch R, Welzel T, Wick W, Debus J. Generation and validation of a prognostic score to predict outcome after reirradiation of recurrent glioma. Acta Oncol 2013;8:147-52.
30. Zheng HX, Cai YD, Wang YD, Cui XB, Xie TT, Li WJ, et al. Fas signaling promotes motility and metastasis through epithelial-mesenchymal transition in gastrointestinal cancer. Oncogene 2013;32:1183-92.
31. de Groot JF, Lamborn K, Chang S, Gilbert MR, Cloughesy TF, Aldape K, et al. Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumour Consortium study. J Clin Oncol 2011; 29:2689-95.
32. Reardon D, Fink K, Mikkelsen T, Cloughesy TF, O'Neill A, Plotkin S, et al. Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol 2008;26:5610-7.
33. van den Bent M, Brandes A, Rampling R, Kouwenhoven MC, Kros JM, Carpentier AF, et al. Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumour group study 26034. J Clin Oncol 2009;27:1268-74.
34. Tsao MN, Mehta MP, Whelan TJ, Morris DE, Hayman JA, Flickinger JC, et al. The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for malignant glioma. Int J Radiat Oncol Biol Phys 2009;63:47-55.
35. nd Annual Meeting of the American Association for Cancer Research; 2011; Washington, DC. Philadelphia (PA): AACR; 2011. Abstract nr LB-382.